Research

UConn Health: Double-Blind Outpatient Study  for Refractory Focal Onset Epilepsy

Inclusion Criteria

• Males and females 18 to 75 years of age
• Diagnosis of Focal Onset Epilepsy (drug resistant) with 4 or more observable focal seizures per month
• Stable regimen with at least 1 and up to 3 anti-seizure medications

Exclusion

• Non focal seizures
• Major ongoing acute or subacute medical issues (e.g. Uncontrolled hypertension, substance abuse, congestive heart failure)

Patient Commitment & Support

• Screening and Observational Phase: 8 weeks with 1 in person visit
• Double-Blind Phase: 8 weeks with 4 in person study visits
• Bio-specimen collection, seizure diary collection, ECG
• Participants will  receive up to $550.00
  • $100.00 for each visit (Visits 1-5)
  • $50.00 for the 2 week  follow up
  • Additional $150.00 for completing at least 85% eDiary entries
• Upon completion, may opt into long term safety study, no placebo involved, only active drug

Sponsor

Biohaven Therapeutics

Contacts

Sheila Thurlow, MSN, RN
P: 860-679-4637   |  E:  thurlow@uchc.edu

Catherine Jahne, BSN, RN
P: 860-679-1138    |  E: jahne@uchc.edu

Praxis: Power2  Study

Interested in participating?

Scan the QR Code below to be directed to the assessment site, to determine eligibility.

Yale: Staccato: Double-Blind Outpatient Study (Efficacy and Safety of Staccato Alprazolam)

Inclusion Criteria

• Age 12 or older. 
• 4 or more prolonged seizures in the past 6 months, 2 of which must have occurred within the past 3 months.
• Must have a study caregiver 18 years or older at the Screening Visit; caregiver(s) should be able:
  • To provides daily care and have a significant personal relationship with the patient.
  • To recognize and observe the patient’s seizures.

Exclusion Criteria

• Atrial fibrillation; mitral stenosis; asthma; chronic pulmonary disorder.

Patient Commitment & Support

• Maximum of approximately 19 weeks (including the screening period, follow-up, and early termination visit).
• Compensation:
  • $150 for each patient on-site study visit (completed) and unscheduled study visits.
  • $100 patient kit exchange visits (completed).
  • $52 patient and caregiver travel to on-site visits.

Contacts

• Kelly Benson-Atwood: kelly.benson-atwood@yale.edu

Yale: Staccato: Open-label Outpatient Study (Safety and Tolerability of Staccato Alprazolam)

Inclusion Criteria

•  Age 12 or older.
• Participant must have completed participation in EP0162 (double-blind study).
• Must have a study caregiver 18 years or older at the Screening Visit; caregiver(s) should be able:
  • To provides daily care and have a significant personal relationship with the patient.
  • To recognize and observe the patient’s seizures.

Exclusion Criteria

• Atrial fibrillation; mitral stenosis; asthma; chronic pulmonary disorder.

Patient Commitment & Support

• Screening/Baseline assessments no more than 6 weeks; Treatment Period: approximately 0 to 4 years
• Compensation:
  •  $150 for each patient on-site study visit (completed).
  • $100 patient kit exchange visits (completed).
  • $52 patient and caregiver travel to on-site visits

Contacts

• Kelly Benson-Atwood: kelly.benson-atwood@yale.edu